{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["59(10)"],"submitter":["Zhang J"],"funding":["Bristol-Myers Squibb"],"pubmed_abstract":["Nivolumab is the first anti-programmed death-1 agent approved in China for treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). Here, we characterize the population pharmacokinetics (PPK) of nivolumab monotherapy in Chinese patients with previously treated advanced/recurrent solid tumors, including NSCLC and nasopharyngeal cancer (NPC), using data from 2 predominantly Chinese (CheckMate 077 and 078), and 5 global (MDX1106-01, CA209-003, and CheckMate 017, 057, and 063) studies. The PPK model was developed by reestimating parameters of a prior global population model with Chinese patient data. Model reestimates showed nivolumab pharmacokinetics (PK) to be linear and dose proportional. Race did not have a clinically meaningful effect on nivolumab clearance. Body we"],"journal":["Journal of clinical pharmacology"],"pagination":["1415-1424"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6767401"],"repository":["biostudies-literature"],"pubmed_title":["Model-Based Population Pharmacokinetic Analysis of Nivolumab in Chinese Patients With Previously Treated Advanced Solid Tumors, Including Non-Small Cell Lung Cancer."],"pmcid":["PMC6767401"],"pubmed_authors":["Sheng J","Bello A","Zhang J","Cai J","Roy A"],"additional_accession":[]},"is_claimable":false,"name":"Model-Based Population Pharmacokinetic Analysis of Nivolumab in Chinese Patients With Previously Treated Advanced Solid Tumors, Including Non-Small Cell Lung Cancer.","description":"Nivolumab is the first anti-programmed death-1 agent approved in China for treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). Here, we characterize the population pharmacokinetics (PPK) of nivolumab monotherapy in Chinese patients with previously treated advanced/recurrent solid tumors, including NSCLC and nasopharyngeal cancer (NPC), using data from 2 predominantly Chinese (CheckMate 077 and 078), and 5 global (MDX1106-01, CA209-003, and CheckMate 017, 057, and 063) studies. The PPK model was developed by reestimating parameters of a prior global population model with Chinese patient data. Model reestimates showed nivolumab pharmacokinetics (PK) to be linear and dose proportional. Race did not have a clinically meaningful effect on nivolumab clearance. Body we","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Oct","modification":"2026-05-07T10:29:35.223Z","creation":"2019-10-11T07:13:12Z"},"accession":"S-EPMC6767401","cross_references":{"pubmed":["31115908"],"doi":["10.1002/jcph.1432"]}}